Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ:GLUE
Want to see GLUE full AI Analyst Report?
Top Page
Monte Rosa Therapeutics
(NASDAQ:GLUE)
Select Model
Select Model
Rating:55Neutral
Price Target:
$20.00
▲(1.11% Upside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak and volatile financial performance (large TTM losses, revenue step-down, and renewed cash burn), partially offset by a relatively strong balance sheet with low leverage. Technicals are moderately supportive with the stock above major moving averages and neutral-to-positive momentum, while valuation metrics provided are not informative due to the non-meaningful P/E and no dividend yield.
Positive Factors
Proprietary QuEEN platform
The QuEEN discovery engine targets previously undruggable proteins via induced degradation, creating a durable scientific moat. A platform-driven model supports multiple programs, spreads R&D leverage across assets, and enhances long-term partner and licensing optionality.
Negative Factors
Cash-flow volatility
Recent return to cash burn undermines runway and increases reliance on partner funding or new financing. Variable cash generation makes planning multiple simultaneous Phase 2 starts riskier and raises the probability of equity dilution if partner milestones do not bridge funding needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary QuEEN platform
The QuEEN discovery engine targets previously undruggable proteins via induced degradation, creating a durable scientific moat. A platform-driven model supports multiple programs, spreads R&D leverage across assets, and enhances long-term partner and licensing optionality.
Read all positive factors
Monte Rosa Therapeutics (GLUE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.59B
Dividend YieldN/A
Average Volume (3M)792.37K
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue Growth-73.07%
EPS Growth-2335.85%
CountryUS
Employees142
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.86
Shares Outstanding84,479,416
10 Day Avg. Volume755,700
30 Day Avg. Volume792,373
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)5.59
Price to Sales (P/S)10.53
P/FCF Ratio-47.37
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue25.71
Enterprise Value/Gross Profit26.98
Enterprise Value/Ebitda-7.89
Forecast
1Y Price Target
$32.80Price Target Upside65.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.64
Revenue Forecast (FY)$46.05M
Monte Rosa Therapeutics Business Overview & Revenue Model
Company Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an o...
How the Company Makes Money
Monte Rosa Therapeutics generates revenue primarily through collaboration and licensing arrangements with larger pharmaceutical partners rather than from product sales, as it is a clinical-stage company. Under these partnerships, the company may e...
Monte Rosa Therapeutics Earnings Call Summary
Earnings Call Date:Mar 20, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly with the success of MRT-6160 and strategic agreement with Novartis. However, challenges such as lower than expected biomarker positivity in certain cancer cohorts and strategic shifts were noted. Overall, the positive developments and financial strength suggest a strong position for future growth.Positive Updates
MRT-6160 Phase 1 Study Success
The Phase 1 SAD/MAD study of MRT-6160 in healthy volunteers showed dose-dependent VAV1 degradation exceeding 90%, with significant inhibition of cytokine secretion up to 99%, and was well tolerated.
Negative Updates
Lower than Expected Biomarker Positivity
In the MRT-2359 Phase 1/2 study, there was a considerably lower than expected frequency of tumors with high L or N-MYC expression, affecting lung cancer and neuroendocrine tumor cohorts.
Read all updates
Q4-2024 Updates
Positive
Negative
MRT-6160 Phase 1 Study Success
The Phase 1 SAD/MAD study of MRT-6160 in healthy volunteers showed dose-dependent VAV1 degradation exceeding 90%, with significant inhibition of cytokine secretion up to 99%, and was well tolerated.
Read all positive updates
Company Guidance
During the Monte Rosa Therapeutics conference call held on March 20, 2025, several key metrics were discussed regarding the company's clinical and preclinical programs. The Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader, demonstrated significant pharmacodynamic effects with over 90% VAV1 degradation and up to 99% cytokine secretion inhibition, supporting progression to Phase 2 trials. The NEK7 program is on track for an IND submission in the first half of the year, with preclinical data showing potent NEK7 degradation and favorable safety profiles. In oncology, promising early data from the MRT-2359 program in castration-resistant prostate cancer showed a confirmed partial response and two stable diseases among three patients, prompting a focus on this indication. Monte Rosa plans to advance these programs with a strong cash runway extending into 2028.Monte Rosa Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
67
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.95M | 123.67M | 75.62M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 40.92M | 115.32M | 67.50M | -6.22M | -8.56M | 0.00 |
| EBITDA | -139.94M | -45.85M | -72.99M | -137.09M | -108.64M | -70.75M |
| Net Income | -130.01M | -38.63M | -72.70M | -135.35M | -108.50M | -73.96M |
Balance Sheet | ||||||
| Total Assets | 736.43M | 448.66M | 438.73M | 303.75M | 342.39M | 366.33M |
| Cash, Cash Equivalents and Short-Term Investments | 666.22M | 377.10M | 372.15M | 232.41M | 262.83M | 346.07M |
| Total Debt | 39.06M | 39.19M | 42.72M | 46.04M | 47.00M | 0.00 |
| Total Liabilities | 214.51M | 215.60M | 215.80M | 124.50M | 70.98M | 18.81M |
| Stockholders Equity | 521.92M | 233.06M | 222.94M | 179.25M | 271.41M | 347.51M |
Cash Flow | ||||||
| Free Cash Flow | -19.66M | -27.50M | 38.01M | -62.84M | -105.38M | -69.09M |
| Operating Cash Flow | -14.68M | -22.80M | 42.00M | -43.80M | -92.47M | -59.36M |
| Investing Cash Flow | -262.60M | -101.83M | -44.45M | 88.80M | -219.22M | -9.65M |
| Financing Cash Flow | 358.67M | 30.35M | 98.89M | 27.49M | 20.47M | 377.56M |
Monte Rosa Therapeutics Technical Analysis
Positive
19.78
Price Trends
17.99
Positive
18.93
Negative
14.63
Positive
Market Momentum
-0.01
Positive
50.38
Neutral
40.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLUE, the sentiment is Positive. The current price of 19.78 is above the 20-day moving average (MA) of 19.03, above the 50-day MA of 17.99, and above the 200-day MA of 14.63, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 50.38 is Neutral, neither overbought nor oversold. The STOCH value of 40.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GLUE.
Monte Rosa Therapeutics Risk Analysis
Monte Rosa Therapeutics disclosed 85 risk factors in its most recent earnings report. Monte Rosa Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Monte Rosa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.59B | ― | -40.99% | ― | -73.07% | -2335.85% | |
55 Neutral | $437.78M | -7.74 | -27.80% | ― | -100.00% | -2365.81% | |
54 Neutral | $1.49B | -7.83 | -563.89% | ― | 550.00% | -107.04% | |
53 Neutral | $818.56M | ― | -36.61% | ― | -75.91% | -173.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $422.84M | -30.03 | -0.02% | ― | ― | 40.38% |
* Healthcare Sector Average
GLUE
Monte Rosa Therapeutics
18.81
14.82
371.43%
CTMX
CytomX Therapeutics
3.76
1.53
68.61%
FULC
Fulcrum Therapeutics
6.57
0.22
3.46%
MNPR
Monopar Therapeutics Inc
63.12
27.67
78.05%
INBX
Inhibrx Biosciences Inc
101.32
88.19
671.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.